Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 626 results for "Tecfidera"

Biogen Inc Q1 Profits Miss Estimates On Slowing Growth In Tecf...

Biogen Inc ( NASDAQ:BIIB ) announced its first-quarter financial results for 2015 before the opening bell on Friday, reporting lower-than-expected growth in its quarterly revenue and profits on the back of slowing sales of its top-selling multiple ... Bidness Etc, 17 hours ago
Biogen Q1 Results Miss Estimates, 1 day ago

27 images for Tecfidera

Monthly Prescribing Reference, 3 days ago
Reuters, 1 day ago
Nasdaq, 1 month ago
Pharma Letter, 2 months ago
Nasdaq, 2 months ago
Nasdaq, 2 months ago
Nasdaq, 4 months ago, 4 months ago
Pharma Letter, 4 months ago
HCPLive, 4 months ago

UPDATE 2-Biogen reports slowing sales of Tecfidera, shares plunge

* Stock falls as much at 8 pct * Tecfidera sales fall 10 pct on sequential basis in 1st qtr * Co also experiencing strong currency headwinds - executives (Adds details, executive and analyst comments; updates shares) ...
 CNBC1 day ago Biogen results disappoint as Tecfidera sales slow  Irish Times1 day ago UPDATE 1-Biogen 1st qtr results disappoint Wall Street as Tecfidera sales slow  CNBC1 day ago Market Update: Biogen Idec Inc (NASDAQ:BIIB) Biogen says Tecfidera sales slow, delays data readout on Alzheimer's drug  Vision Monday1 day ago

Biogen Drops as Profit Disappoints Amid Slow Tecfidera Sales

(Updates with closing share price in fifth paragraph.) Earnings excluding one-time items rose to $3.82 a share from $2.47 a year earlier. Analysts had forecast $3.88 on average, according to estimates compiled by Bloomberg. Revenue increased 20 ...
 Washington Post1 day ago Biogen Profit Trails Estimates as Tecfidera Growth Slows  Washington Post1 day ago

Biogen Inc (BIIB) Stock Price Tumbles 8% After Sales Of Multiple Sclerosis Drug Tecfidera Miss Analyst Estimate In Q1

The share price of Biogen Inc. (NASDAQ:BIIB) tumbled as much as 8 percent, to $395, Friday after sales of the biotechnology company's multiple-sclerosis drug Tecfidera came in below the analysts' consensus estimate for the first quarter. With a ...
 Austin American Statesman1 day ago Biogen 1st qtr profit jumps 71 pct as MS drug Tecfidera shines  CNBC1 day ago Biogen sales, profit miss the mark as Tecfidera flags  FiercePharma1 day ago Biogen's first-quarter revenue up 20 percent, but misses estimates as Tecfidera sales fall short  FirstWord Pharma1 day ago

Biogen Q1 Misses Estimates As Tecfidera Stalls

B ig-cap biotech Biogen (NASDAQ: BIIB ) missed Wall Street's Q1 estimates Friday as its multiple-sclerosis drug Tecfidera ran into unexpected headwinds, sending its stock down to a two-month low in early trading. Biogen's earnings excluding ...
 Investor's Business Daily1 day ago Biogen's MS Drug Sales Light, Alzheimer's Data Pushed Back  Yahoo! Singapore1 day ago

Biogen Misses on 1Q Earnings, Tecfidera Falls Short - Analyst Blog

Biotech company, Biogen BIIB, reported first quarter 2015 earnings per share of $3.82 (including the impact of stock-based compensation expense), well below the Zacks Consensus Estimate of $3.91 but 55.9% above the year-ago earnings. Biogen Idec ...
 Yahoo! Finance1 day ago

Biogen's Weak Tecfidera Sales in 1Q Don't Affect Our Fair Value Estimate

We don't recognize that email. Please try again. Forgot Password? Password Please enter your password. The password you entered does not match our records. Please try again. Our records show you have a Morningstar account, but you are not ...
 Morningstar.com1 day ago

Hedge fund honcho eyes Biogen patent covering top-selling Tecfidera

News Editor Hedge fund investor Kyle Bass, head of Dallas, TX-based Hayman Capital Management L.P., files a challenge to a key patent covering Biogen's (BIIB +0.6%) $2.9B Tecifera (dimethyl fumarate). Specifically, he is challenging the validity ...
 Seeking Alpha3 days ago Bass Challenges Patent on Biogen's Blockbuster Tecfidera  FINalternatives2 days ago Celgene, Shire Make Five as Kyle Bass Expands Drug Patent Fight  Bloomberg2 days ago Strategies for Pharma Companies Facing Bass-Like Challenges in IPR Proceedings  JD Supra2 days ago
Monthly Prescribing Reference

Biogen : Tecfidera Data Reinforce Efficacy For Newly-Diagnosed MS Patients

Biogen (BIIB: Quote) announced new data that continue to support Tecfidera or dimethyl fumarate as an effective, long-term treatment for people who are living with relapsing forms of multiple sclerosis or MS. The data show Tecfidera significantly ...
 RTTNews.com5 days ago New Data Released for Tecfidera in Multiple Sclerosis  Monthly Prescribing Reference5 days ago TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients  Fat Pitch Financials5 days ago TECFIDERA (dimethyl fumarate) data reinforce strong, sustained efficacy for newly-diagnosed MS patients  Medical News Today3 days ago

Tecfidera, first-line oral treatment for multiple sclerosis, approved in India13-02-2015

US biotech major Biogen Idec's Indian subsidiary has received approval of the first oral therapy for… In order to access this content you need to be logged into the site and have an active subscription or trial subscription. Please login , take ...
 Pharma Letter2 months ago Biogen gets approval of oral therapy for multiple sclerosis  Business Standard2 months ago New oral treatment for multiple sclerosis approved for use in Canada  CTV News2 months ago Biogen Idec gets DCGI nod for multiple sclerosis oral drug  Business Standard2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Tecfidera
Get updated on latest news & your favorite topics right in your inbox!
More     Less